Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Therapeutic options beyond AR pathway inhibitors: What do we choose next?

Will theranostics become standard of care?

Date

13 Sep 2024

Session

Therapeutic options beyond AR pathway inhibitors: What do we choose next?

Topics

Tumour Site

Prostate Cancer

Presenters

Silke Gillessen

Authors

S. Gillessen

Author affiliations

  • Medical Oncology Department, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), 6500 - Bellinzona/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and discussion

Session: Therapeutic options beyond AR pathway inhibitors: What do we choose next?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.